Investor Presentaiton
121
Investor presentation Full year 2022
Region China at a glance.
Million
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Region China
Novo Nordisk reported sales
DKK
billion
Full year 2022
Sales
(mDKK)
Growth²
200
30
100%
6%
Total GLP-13
3,737
88%
14%
160
22
GLP-1
25
80%
Long-acting insulin
1,636
-27%
86.8%¹
Premix insulin5
4,912
-13%
20
120
60%
Fast-acting insulin
1,942
-21%
Insulin
9.3%1
15
Human insulin
175
1,812
-38%
80
164
40%
141
10
10
Total insulin
10,302
-22%
40
40
Other Diabetes care?
1,181
-24%
5
9.9%1
20%
OAD
Diabetes care
15,220
-9%
0
2021
0
0%
Obesity care
133
105%
Nov
2030
2045
2017
Population with diabetes
Diabetes growth rate
-GLP-1 MS
-Insulin MS
Nov
2022
-OAD MS
Diabetes & Obesity care
15,353
-9%
Rare disease8
856
101%
Total
16,209
-6%
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
Region China covers Mainland China, Taiwan, and Hong Kong
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Nov 2022: Novo Nordisk 52%, Sanofi 15%,
Gan & Lee 0.1% and Eli Lilly 7%; Competitor GLP-1 value market shares, as of Nov 2022:
Novo Nordisk 64% and Eli Lilly 29%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Nov 2022 value figures
4
2 At constant exchange rates; 3 Comprises VictozaⓇ and OzempicⓇ;
Comprises Tresiba®, XultophyⓇ and Levemir®: 5 Comprises NovoMixⓇ and
RyzodegⓇ: 6 Comprises NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ; 9 Comprises primarily Novo Seven®, Novo Eight® and
NorditropinⓇView entire presentation